231 related articles for article (PubMed ID: 15539550)
1. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth.
Warden SJ; Robling AG; Sanders MS; Bliziotes MM; Turner CH
Endocrinology; 2005 Feb; 146(2):685-93. PubMed ID: 15539550
[TBL] [Abstract][Full Text] [Related]
2. [Effect of SSRIs on bone metabolism].
Kerbage H; Bahadori S; Léger J; Carel JC; Purper Ouakil D
Encephale; 2014 Feb; 40(1):56-61. PubMed ID: 23810751
[TBL] [Abstract][Full Text] [Related]
3. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency.
Warden SJ; Nelson IR; Fuchs RK; Bliziotes MM; Turner CH
Menopause; 2008; 15(6):1176-83. PubMed ID: 18725867
[TBL] [Abstract][Full Text] [Related]
4. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice.
Ansorge MS; Zhou M; Lira A; Hen R; Gingrich JA
Science; 2004 Oct; 306(5697):879-81. PubMed ID: 15514160
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130.
Taber MT; Wright RN; Molski TF; Clarke WJ; Brassil PJ; Denhart DJ; Mattson RJ; Lodge NJ
Pharmacol Biochem Behav; 2005 Mar; 80(3):521-8. PubMed ID: 15740795
[TBL] [Abstract][Full Text] [Related]
6. Serotonin and its antidepressant-sensitive transport in mouse cumulus-oocyte complexes and early embryos.
Amireault P; Dubé F
Biol Reprod; 2005 Aug; 73(2):358-65. PubMed ID: 15858217
[TBL] [Abstract][Full Text] [Related]
7. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Marcos E; Adnot S; Pham MH; Nosjean A; Raffestin B; Hamon M; Eddahibi S
Am J Respir Crit Care Med; 2003 Aug; 168(4):487-93. PubMed ID: 12773327
[TBL] [Abstract][Full Text] [Related]
8. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
Chen F; Larsen MB; Sánchez C; Wiborg O
Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064
[TBL] [Abstract][Full Text] [Related]
9. Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels.
Warden SJ; Hassett SM; Bond JL; Rydberg J; Grogg JD; Hilles EL; Bogenschutz ED; Smith HD; Fuchs RK; Bliziotes MM; Turner CH
Bone; 2010 Apr; 46(4):985-92. PubMed ID: 20060080
[TBL] [Abstract][Full Text] [Related]
10. Serotonin regulates osteoclast differentiation through its transporter.
Battaglino R; Fu J; Späte U; Ersoy U; Joe M; Sedaghat L; Stashenko P
J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242
[TBL] [Abstract][Full Text] [Related]
11. 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent.
Song D; Wang HL; Wang S; Zhang XH
Acta Pharmacol Sin; 2005 May; 26(5):563-7. PubMed ID: 15842774
[TBL] [Abstract][Full Text] [Related]
12. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
Bianchi M; Moser C; Lazzarini C; Vecchiato E; Crespi F
Exp Brain Res; 2002 Mar; 143(2):191-7. PubMed ID: 11880895
[TBL] [Abstract][Full Text] [Related]
13. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies.
Warden SJ; Haney EM
J Musculoskelet Neuronal Interact; 2008; 8(2):121-32. PubMed ID: 18622081
[TBL] [Abstract][Full Text] [Related]
14. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter.
Fabre V; Beaufour C; Evrard A; Rioux A; Hanoun N; Lesch KP; Murphy DL; Lanfumey L; Hamon M; Martres MP
Eur J Neurosci; 2000 Jul; 12(7):2299-310. PubMed ID: 10947809
[TBL] [Abstract][Full Text] [Related]
15. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
Hirano K; Kimura R; Sugimoto Y; Yamada J; Uchida S; Kato Y; Hashimoto H; Yamada S
Br J Pharmacol; 2005 Mar; 144(5):695-702. PubMed ID: 15678084
[TBL] [Abstract][Full Text] [Related]
16. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries.
Morecroft I; Loughlin L; Nilsen M; Colston J; Dempsie Y; Sheward J; Harmar A; MacLean MR
J Pharmacol Exp Ther; 2005 May; 313(2):539-48. PubMed ID: 15659538
[TBL] [Abstract][Full Text] [Related]
17. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.
Jones DC; Lau SS; Monks TJ
J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827
[TBL] [Abstract][Full Text] [Related]
18. Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity.
Mannoury la Cour C; Boni C; Hanoun N; Lesch KP; Hamon M; Lanfumey L
J Neurosci; 2001 Mar; 21(6):2178-85. PubMed ID: 11245702
[TBL] [Abstract][Full Text] [Related]
19. Serotonin transporter in substance P (neurokinin 1) receptor knock-out mice.
David DJ; Froger N; Guiard B; Przybylski C; Jego G; Boni C; Hunt SP; De Felipe C; Hamon M; Jacquot C; Gardier AM; Lanfumey L
Eur J Pharmacol; 2004 May; 492(1):41-8. PubMed ID: 15145704
[TBL] [Abstract][Full Text] [Related]
20. (+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-hydroxytryptamine or 5-hydroxytryptamine transporter.
Ni W; Wilhelm CS; Bader M; Murphy DL; Lookingland K; Watts SW
J Pharmacol Exp Ther; 2005 Sep; 314(3):953-60. PubMed ID: 15901794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
